Literature DB >> 22184093

SOX2 contributes to melanoma cell invasion.

Sasha D Girouard1, Alvaro C Laga, Martin C Mihm, Richard A Scolyer, John F Thompson, Qian Zhan, Hans R Widlund, Chung-Wei Lee, George F Murphy.   

Abstract

The mechanisms of melanoma invasion are poorly understood despite extensive inquiry. SRY (sex determining region Y)-box 2 (SOX2) is an embryonic stem cell transcription factor that has recently been discovered to be expressed in human melanoma where it is associated with dermal invasion and primary tumor thickness. To assess the potential role of SOX2 expression in melanoma invasion, we examined patient melanomas and humanized melanoma xenografts, and noted preferential SOX2 expression in cells that interfaced and infiltrated dermal stroma. Experimental knockdown (KD) of SOX2 mRNA and protein in A2058 melanoma cells with high constitutive SOX2 expression resulted in 4.5-fold decreased invasiveness in vitro compared with controls (P<0.0001). Conversely, when G361 cells that normally express low SOX2 were transduced to overexpress SOX2 mRNA and protein, a 3.8-fold increase in invasiveness was observed (P=0.0004). Among 84 invasion-related genes, RT-PCR screening revealed that SOX2 KD resulted in striking decrease in matrix metalloproteinase-3 (MMP-3), an endopeptidase associated with cleavage of the extracellular matrix. Quantitatively, SOX2 KD diminished MMP-3 mRNA by 87.8%. MMP-3 KD in SOX2-expressing A2058 cells served to inhibit invasion, although to a lesser degree than SOX2 KD. Finally, immunostaining of patient and xenograft melanomas revealed coordinate SOX2 and MMP-3 expression in regions of stromal infiltration. These data implicate SOX2 expression in melanoma invasion, and suggest a role for MMP-3 as one potential mediator of this process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22184093      PMCID: PMC3887365          DOI: 10.1038/labinvest.2011.188

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  32 in total

1.  Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer.

Authors:  A O Güre; E Stockert; M J Scanlan; R S Keresztes; D Jäger; N K Altorki; L J Old; Y T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 3.  Mechanisms of early neural crest development: from cell specification to migration.

Authors:  C Kalcheim
Journal:  Int Rev Cytol       Date:  2000

Review 4.  Neural crest cells: a model for invasive behavior.

Authors:  Richard P Tucker
Journal:  Int J Biochem Cell Biol       Date:  2004-02       Impact factor: 5.085

5.  Vertebrate neurogenesis is counteracted by Sox1-3 activity.

Authors:  Magdalena Bylund; Elisabeth Andersson; Bennett G Novitch; Jonas Muhr
Journal:  Nat Neurosci       Date:  2003-09-28       Impact factor: 24.884

Review 6.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

7.  High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.

Authors:  Johanna Nikkola; Pia Vihinen; Tatyana Vlaykova; Marjo Hahka-Kemppinen; Veli-Matti Kähäri; Seppo Pyrhönen
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

8.  Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma.

Authors:  R A Walker; D E Woolley
Journal:  Virchows Arch       Date:  1999-12       Impact factor: 4.064

9.  Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis.

Authors:  B Bodey; B Bodey; S E Siegel; H E Kaiser
Journal:  In Vivo       Date:  2001 Jan-Feb       Impact factor: 2.155

10.  Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma.

Authors:  Xue-Ling Li; Yoshinobu Eishi; Yun-Qing Bai; Hidekazu Sakai; Yoshimitsu Akiyama; Masao Tani; Touichirou Takizawa; Morio Koike; Yasuhito Yuasa
Journal:  Int J Oncol       Date:  2004-02       Impact factor: 5.650

View more
  53 in total

Review 1.  Stem cells and targeted approaches to melanoma cure.

Authors:  George F Murphy; Brian J Wilson; Sasha D Girouard; Natasha Y Frank; Markus H Frank
Journal:  Mol Aspects Med       Date:  2013-10-19

2.  The extracellular domain of epithelial cell adhesion molecule (EpCAM) enhances multipotency of mesenchymal stem cells through EGFR-LIN28-LET7 signaling.

Authors:  I-I Kuan; Chi-Chiu Lee; Chien-Hsu Chen; Jean Lu; Yuan-Sung Kuo; Han-Chung Wu
Journal:  J Biol Chem       Date:  2019-03-29       Impact factor: 5.157

3.  Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients.

Authors:  Julia Shih; Munira Rahman; Quang T Luong; Shirley H Lomeli; Joseph Riss; Robert M Prins; Ali O Gure; Gang Zeng
Journal:  Am J Clin Exp Immunol       Date:  2014-08-15

4.  Melanoma spheroid formation involves laminin-associated vasculogenic mimicry.

Authors:  Allison R Larson; Chung-Wei Lee; Cecilia Lezcano; Qian Zhan; John Huang; Andrew H Fischer; George F Murphy
Journal:  Am J Pathol       Date:  2014-01       Impact factor: 4.307

5.  Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.

Authors:  V Cesarini; E Guida; F Todaro; S Di Agostino; V Tassinari; S Nicolis; R Favaro; S Caporali; P M Lacal; E Botti; A Costanzo; P Rossi; E A Jannini; S Dolci
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

6.  Sox2 is dispensable for primary melanoma and metastasis formation.

Authors:  S M Schaefer; C Segalada; P F Cheng; M Bonalli; V Parfejevs; M P Levesque; R Dummer; S K Nicolis; L Sommer
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 7.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

Authors:  Ross L Pearlman; Mary Katherine Montes de Oca; Harish Chandra Pal; Farrukh Afaq
Journal:  Cancer Lett       Date:  2017-01-25       Impact factor: 8.679

8.  A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.

Authors:  Diane D Mao; Amit D Gujar; Tatenda Mahlokozera; Ishita Chen; Yanchun Pan; Jingqin Luo; Taylor Brost; Elizabeth A Thompson; Alice Turski; Eric C Leuthardt; Gavin P Dunn; Michael R Chicoine; Keith M Rich; Joshua L Dowling; Gregory J Zipfel; Ralph G Dacey; Samuel Achilefu; David D Tran; Hiroko Yano; Albert H Kim
Journal:  Cell Rep       Date:  2015-06-11       Impact factor: 9.423

Review 9.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

10.  Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma.

Authors:  Mohammad Mahdi Forghanifard; Sima Ardalan Khales; Afsaneh Javdani-Mallak; Abolfazl Rad; Moein Farshchian; Mohammad Reza Abbaszadegan
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.